The company's shares have seen a decrease of 2.93% over the last month, not keeping up with the Medical sector's gain of 0.37% and the S&P 500's gain of 1.96%. CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.51 per share and revenue of $89.43 million. These results would represent year-over-year changes of -184.02% and -75.91%, respectively. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have d ...

We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports second-quarter 2024 results next month. The Zacks Consensus Estimate for CRSP's total revenues currently stands at $8.39 million. CRISPR Therapeutics has a positive earnings surprise history. The company beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 117.78%. In the last reported quarter, CRSP's earnings beat estimates by 12.27%. Other Stocks to Consider Amgen Inc. (AMGN) has an Ear ...

California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Prosper Junior Bakiny (CRISPR Therapeutics): It's always an important milestone for a clinical-stage biotech to launch its first product. That's what happened with CRISPR Therapeutics last year. The gene-editing specialist earned approval for Casgevy, developed in collaboration with Vertex Pharmaceutic ...

Other purposes of gene editing include making crops more resistant to viruses and bacteria and better able to cope with extremes of heat and cold caused by global warming. One day, gene editing could alter people's DNA and prevent certain diseases from developing. In some circles, gene editing is controversial, though the science behind it is widely viewed as legitimate. Source: rafapress / Shutterstock.com Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals is a more mature and established biotech company ...

CRISPR Therapeutics AG (CRSP) shares ended the last trading session 9.2% higher at $62.75. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7% loss over the past four weeks. This rise in share price is attributable to positive investor expectations for the company's sole-marketed product Casgevy which received marketing approval in late 2023/early 2024. Marketed in partnership with Vertex Pharmaceuticals, Casgevy is ...

That said, it's not a good idea to rely on six months' worth of data to decide which stocks to buy. These two biotechs will likely reverse positions over the long run, with CRISPR performing much better than Ocugen. Read on to find out why the former is worth investing in while the latter should be avoided. Now, it's too early to look at CRISPR Therapeutics' financial results. Casgevy hasn't been on the market very long, not to mention that administering this therapy takes a while. The biotech's revenue in ...

The company's stock has dropped by 11.68% in the past month, falling short of the Medical sector's loss of 1.82% and the S&P 500's gain of 4.44%. For the full year, the Zacks Consensus Estimates project earnings of -$5.51 per share and a revenue of $89.43 million, demonstrating changes of -184.02% and -75.91%, respectively, from the preceding year. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a pro ...

But the silver lining of that process is you have time to accumulate a position. And, by not going all in, there's time to evaluate your thesis for owning the stock as time goes by. Here are three biotech stocks to buy while they're still in their early stages of growth. Recently, CRISP received Food and Drug Administration (FDA) approval for CASGEVY, its lead candidate for treatment of sickle cell disease and beta-thalassemia. This treatment is now available in 25 authorized centers around the world. Cassa ...

Biotech stocks to buy now reflect a more dynamic shift in investor focus of late. Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023. The vaccine rollout was hugely successful across the globe, especially in countries like the U.S., U.K. and Germany. That said, here are three compelling biotech stocks that fit the bill and have the potential to brighten ...

文章核心观点 - 尽管CRISPR Therapeutics的股票在过去一年中一直呈现横盘走势,但短期内可能会迎来更好的日子[1] - CRISPR Therapeutics成功推进其基因编辑疗法Casgevy通过临床试验,并在多个地区获得监管批准,包括美国、英国、欧盟和沙特阿拉伯[3] - CRISPR Therapeutics正与生物科技巨头Vertex Pharmaceuticals合作,华尔街预计Casgevy未来将达到每年10亿美元的销售额[4] - 尽管如此,CRISPR Therapeutics的股价在过去12个月中几乎没有变动[4] 公司相关 - CRISPR Therapeutics正在开发其他管线产品,涉及肿瘤、自身免疫、糖尿病和心血管疾病等领域[8] - Casgevy的商业化需要一年或更长时间才能真正起步,这需要投资者的耐心[8] - Casgevy作为一种基因疗法,其给药过程复杂,需要专业设施和专业知识,这意味着在最初几个季度不会有太高的渗透率[10][11] 行业相关 - 创新型股票为投资者带来了双刃剑,既有巨大的潜力,也有重大的风险[2] - 将概念转化为可商业化的产品或服务是一个复杂、耗时且资金密集的过程,监管障碍、技术挫折或市场需求的变化都可能阻碍最有前景的创新[2]